Delivery Order SPE2DR25D1017-SPE2DR26F9CVS
- Not listed
- The Defense Logistics Agency awarded a $13,813.12 firm fixed price delivery order to AmerisourceBergen Drug Corp for Visipaque 320 mg/ml in 100ml bottles, with an ultimate completion date of December 8, 2025. This competitively awarded, non-set-aside contract represents a single delivery order for a contrast media pharmaceutical product commonly used in diagnostic imaging procedures. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,454.80 to AmerisourceBergen Drug Corp for the supply of Visipaque 320 mg/mL in 100 mL bottles. This firm fixed-price delivery order, issued on December 9, 2025, with an ultimate completion date of December 10, 2025, represents a non-competitive award under the company's existing contract vehicle with DLA. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a...
- The Defense Logistics Agency (DLA) awarded a $7,597.00 delivery order to AmerisourceBergen Drug Corp for Visipaque 320 mg/ml in 100ml bottles, with an ultimate completion date of November 6, 2025. This non-set-aside, firm fixed price contract represents a child order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The order will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $3,337.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Visipaque 320 mg/mL, a contrast medium supplied in 100 mL bottles. This non-competitive delivery order, issued on October 31, 2025, with an ultimate completion date of November 3, 2025, represents a child contract action under AmerisourceBergen's larger pharmaceutical supply agreements with DLA. The product will be delivered to the contractor's facility in Conshohocken,...
- The Defense Logistics Agency awarded a $2,503.35 delivery order to AmerisourceBergen Drug Corp on October 14, 2025, for the supply of Visipaque 320 mg/ml in 100ml bottles, a contrast medium used in medical imaging procedures. This firm fixed-price delivery order, which represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX valued at $999,999,999.00 through December 2026), carries no set-aside designation and is scheduled...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Visipaque 320 mg/ml in 100 ml bottles, a contrast medium used in medical imaging procedures. This firm fixed-price delivery order, valued at $2,322.46, was competitively awarded without a set-aside designation and carries a completion date of December 12, 2025. AmerisourceBergen will perform delivery from its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a $4,246.40 delivery order to AmerisourceBergen Drug Corp for Visipaque 320 mg/mL infusion bottles (150 mL) on September 24, 2025, with completion expected by September 25, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a single line-item procurement of this contrast medium...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 5, 2025, for the supply of Visipaque 320 mg/mL infusion bottles (150 mL units) with a ceiling value of $1,753.42. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The contract is set to be completed by November 6, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $1,118.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Visipaque 320 mg/mL infusion bottles (150 mL) with an ultimate completion date of January 5, 2026. This non-set-aside contract was competitively awarded and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be...
- The Defense Logistics Agency awarded a delivery order valued at $6,475.92 to AmerisourceBergen Drug Corp for Visipaque 320 mg/ml in 100ml bottles, with an ultimate completion date of December 5, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor's Corporate Office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- SPE2DR25D1017Indefinite Delivery Contract
- SPE2DR25D1017-SPE2DR26F9CVSDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,750.69 to Amerisourcebergen Drug Corp (parent company Cencora, Inc.) on January 8, 2026, with completion scheduled for January 9, 2026. This non-competitive delivery order procures Visipaque 320 mg/ml in 100ml bottles, a contrast agent used in medical imaging procedures. The order is structured as a firm fixed-price delivery order, which is a task order placed against an existing indefinite delivery contract (IDC) with the DLA. Performance will occur at Amerisourcebergen's facility in Conshohocken, Pennsylvania. This delivery order is executed under Amerisourcebergen's existing $999,999,999.00 Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), which runs through December 2026 and serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. Amerisourcebergen Drug Corp, as a major pharmaceutical distributor, fulfills critical medical supply needs across multiple therapeutic domains for the Department of Defense and other federal healthcare systems. The non-set-aside designation reflects the company's competitive capability to deliver pharmaceutical products and medical supplies through open federal procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.8k | 1/7/26 |